FILANA THERAPEUTICS, INC. financial data

Symbol
SAVA on Nasdaq
Location
Austin, TX
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 12 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 290% % -16%
Debt-to-equity 41% %
Return On Assets -69% % -456%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 48,307,896 shares 0%
Common Stock, Shares, Outstanding 48,307,896 shares 0.22%
Entity Public Float $87,000,000 USD -84%
Common Stock, Value, Issued $48,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 48,297,000 shares 4.2%
Weighted Average Number of Shares Outstanding, Diluted 48,297,000 shares 3.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $26,590,000 USD -62%
General and Administrative Expense $68,800,000 USD -4.2%
Operating Income (Loss) $95,390,000 USD 33%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $90,973,000 USD -274%
Earnings Per Share, Basic -1.88 USD/shares -255%
Earnings Per Share, Diluted -1.88 USD/shares -29%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $95,502,000 USD -26%
Other Assets, Current $64,000 USD 68%
Assets, Current $97,709,000 USD -28%
Property, Plant and Equipment, Net $20,646,000 USD -1.7%
Intangible Assets, Net (Excluding Goodwill) $37,000 USD -79%
Assets $118,355,000 USD -25%
Employee-related Liabilities, Current $1,625,000 USD 20%
Liabilities, Current $43,834,000 USD 273%
Other Liabilities, Noncurrent $118,000 USD 49%
Liabilities $43,952,000 USD 272%
Retained Earnings (Accumulated Deficit) $496,084,000 USD -22%
Stockholders' Equity Attributable to Parent $74,403,000 USD -49%
Liabilities and Equity $118,355,000 USD -25%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $11,336,000 USD 41%
Net Cash Provided by (Used in) Financing Activities $90,000 USD -100%
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 120,000,000 shares 0%
Common Stock, Shares, Issued 48,307,896 shares 0.22%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $188,978,000 USD 33%
Deferred Tax Assets, Valuation Allowance $111,896,000 USD 16%
Deferred Tax Assets, Gross $111,898,000 USD 16%
Depreciation $903,000 USD -5.1%
Payments to Acquire Property, Plant, and Equipment $0 USD
Property, Plant and Equipment, Gross $24,785,000 USD 2.3%
Deferred Tax Assets, Operating Loss Carryforwards $78,632,000 USD 82%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $9,020,000 USD -2.4%
Operating Lease, Payments $0 USD -100%
Additional Paid in Capital $570,439,000 USD 3.6%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets $180,000 USD -60%
Deferred Tax Assets, Net of Valuation Allowance $2,000 USD
Share-based Payment Arrangement, Expense $19,582,000 USD 20%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%